AI-Driven CRISPR-Cas9 sgRNA Design for PDCD1, TRAC, and B2M Knockout to Improve CAR T Cell Therapy

The preprint operates within the dominant paradigm of gene editing using CRISPR-Cas9 technology for CAR T-cell therapy. It adheres to the established methodology of sgRNA design and validation, focusing on improving existing techniques rather than proposing radical shifts.

This preprint demonstrates normal science by refining established techniques within the CRISPR-Cas9 paradigm. The authors utilize existing bioinformatics tools and established criteria for sgRNA design and selection, focusing on enhancing efficacy and minimizing off-target effects. Their work contributes to the cumulative progress of the field by optimizing existing methods for improved CAR T-cell therapy. It doesn't challenge the current paradigm or introduce revolutionary concepts, but rather contributes incrementally to our understanding and application of CRISPR technology within the accepted framework. There is no evidence of paradigm shift, model crisis, or model revolution. While it is strictly normal science, it could also be considered model drift, if one broadens the term to encompass refinements and optimizations within a stable paradigm. However, since the core principles of CRISPR technology remain unchallenged, "normal science" appears the most accurate classification.